Inhibikase Therapeutics Inc (IKT) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Inhibikase Therapeutics Inc

NASDAQ | IKT

1.98

USD

-0.205 (-9.40%)

AT CLOSE (AS OF Apr 3, 2025)

$174M

MARKET CAP

P/E Ratio

-3.09

EPS

$4.2

52 Week High

$1.1

52 Week Low

LIFE SCIENCES

Sector

IKT Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IKT Technicals

Tags:

IKT Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$5.4M
Total Revenue	$1.3M
Cost Of Revenue	$6.7M
Costof Goods And Services Sold	$14M
Operating Income	-$20M
Selling General And Administrative	$6.7M
Research And Development	$14M
Operating Expenses	$20M
Investment Income Net	-
Net Interest Income	$1.1M
Interest Income	$891K
Interest Expense	$74K
Non Interest Income	$261K
Other Non Operating Income	-
Depreciation	$177K
Depreciation And Amortization	$177K
Income Before Tax	-$25M
Income Tax Expense	-$6.4M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$14M
Comprehensive Income Net Of Tax	-$33M
Ebit	-$20M
Ebitda	-$20M
Net Income	-$19M

Revenue & Profitability

Earnings Performance

IKT Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$15M
Total Current Assets	$14M
Cash And Cash Equivalents At Carrying Value	$9.2M
Cash And Short Term Investments	$13M
Inventory	$1.1M
Current Net Receivables	-
Total Non Current Assets	$296K
Property Plant Equipment	$73K
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$4.1M
Long Term Investments	-
Short Term Investments	$4.1M
Other Current Assets	$959K
Other Non Current Assets	-
Total Liabilities	$3.5M
Total Current Liabilities	$3.4M
Current Accounts Payable	$647K
Deferred Revenue	-
Current Debt	$150K
Short Term Debt	$532K
Total Non Current Liabilities	$90K
Capital Lease Obligations	$240K
Long Term Debt	$382K
Current Long Term Debt	$150K
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$382K
Other Current Liabilities	$2.3M
Other Non Current Liabilities	-
Total Shareholder Equity	$11M
Treasury Stock	-
Retained Earnings	-$67M
Common Stock	$6.2K
Common Stock Shares Outstanding	$6.2M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$18M
Payments For Operating Activities	$23K
Proceeds From Operating Activities	$382K
Change In Operating Liabilities	-$643K
Change In Operating Assets	$16K
Depreciation Depletion And Amortization	$177K
Capital Expenditures	$14K
Change In Receivables	-$40K
Change In Inventory	-
Profit Loss	-$14M
Cashflow From Investment	$12M
Cashflow From Financing	$8.4M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$8.5M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$8.5M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$19M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$5.4M
Total Revenue	$1.3M
Cost Of Revenue	$6.7M
Costof Goods And Services Sold	$14M
Operating Income	-$20M
Selling General And Administrative	$6.7M
Research And Development	$14M
Operating Expenses	$20M
Investment Income Net	-
Net Interest Income	$1.1M
Interest Income	$891K
Interest Expense	$74K
Non Interest Income	$261K
Other Non Operating Income	-
Depreciation	$177K
Depreciation And Amortization	$177K
Income Before Tax	-$25M
Income Tax Expense	-$6.4M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$14M
Comprehensive Income Net Of Tax	-$33M
Ebit	-$20M
Ebitda	-$20M
Net Income	-$19M

IKT Profile

Inhibikase Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.34	-2.30%	$7.67B	187,389,814
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
ABBV	$202.45	-1.34%	$364.89B	5,252,004
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669